Driven By Research
Managing money since 1992, Emerald is an institutional asset management firm specializing in equity and high grade fixed income portfolio management. The Emerald family of advisors includes Emerald Advisers, Inc., Emerald Mutual Fund Advisers Trust, and Emerald Fixed Income Advisers, LLC. Headquartered in Lancaster, Pennsylvania our award-winning team of research analysts adheres to an intense fundamental research process resulting in over 2,000 company visits a year. This proprietary process is noted for uncovering early investment opportunities that after passing rigorous review are included in a variety of unique growth oriented separate account and mutual fund equity portfolios. In addition, short, mid and long-term fixed income separate account strategies are available, which utilize a combination of proprietary quantitative models and fundamental analysis yielding portfolios of high quality liquid securities.
Emerald Daily Jewel
- Dow Finishes 128 Points Higher on Jobs Report: Stocks rose after the government offered a much less dour assessment of the labor market than had been expected. … read more
Investment Advisory Services
Emerald Advisers, Inc.
Emerald Advisers, Inc. offers equity investment products for those seeking small and mid capitalization growth as well as large capitalization core positions. Our offerings:
Emerald Fixed Income Advisers, LLC
Emerald Fixed Income Advisers, LLC Offers short, intermediate, and long-term products for those seeking high-quality fixed income strategies. Our offering:
Emerald Mutual Fund Advisers Trust
EMFAT is a wholly-owned subsidiary of Emerald Advisers, Inc. and was established to allow for Emerald to serve in a sub-advisor capacity for mutual fund and other registered investment companies. EMFAT currently is the sub-advisor for the Forward Emerald Mutual Funds which include:
Current Events
- Emerald's Case for Small Cap Investing in Technology 2010-06-09
- Emerald Portfolio Management Team provides a case for investing in Small Cap Growth 2009-12-10
- A Case for Small Cap Investing: Biotech 2009-12-09



